ABSTRACT Background: It has been hypothesized that hip-fracture rates are higher in developed than in developing countries because high-protein (HP) Western diets induce metabolic acidosis and hypercalciuria. Confounders include interactions between dietary protein and calcium, sodium, and potassium. Objective: We determined whether an HP or a high-normal-protein (HNP) weight-loss diet caused greater loss in bone mineral density (BMD) over 24 mo. .27] postmenopausal women, with a total hip BMD t score less than 22.0. Subjects were randomly assigned to receive an isocaloric calcium-replete HP ($90 g protein/d) or HNP (,80 g protein/d) weight-loss diet, with the aim of a difference of 20 g protein/d. A total of 186 subjects (90 subjects in the HP group, 96 subjects in the HNP group) completed 12 mo, and 137 subjects (69 subjects in the HP group, 68 subjects in the HNP group) completed 24 mo. Results: Biomarkers confirmed a difference in protein intake of 16 and 13.1 g at 12 and 24 mo, respectively. Mean (6SE) weight loss was equal; HP subjects lost 7.9 6 0.9 kg and HNP subjects lost 8.9 6 0.9 kg at 24 mo. Subjects lost 1-2% BMD annually at lumbar spine vertebrae 2-4, the forearm, the femoral neck, and hip. ANCOVA showed no effect of the HP or HNP diet (P . 0.05 for diet and diet-time interactions). A diet-by-time analysis showed that the HNP diet increased C-terminal telopeptide and osteocalcin (P # 0.001 for each) despite hypercalciuria (P = 0.029). Conclusion: High dietary protein intake during weight loss has no clinically significant effect on bone density but slows bone turnover. This trial was registered at the Australian and New Zealand Clinical Trials Registry (http://www.anzctr.org.au) as ACTRN12608000229370. Am J Clin Nutr 2013;98:1343-52.
INTRODUCTION
The link between protein consumption and bone health has been debated for 40 y. In 1968, Wachman and Bernstein hypothesized that Western diets that contained meat (a source of "acid ash") caused a low-grade metabolic acidosis, which would be buffered by bone causing secondary hypercalciuria (1) . The authors contended that a loss of 2 mEq Ca/d would translate to a 15% loss of bone in a decade and was a cause of osteoporosis.
Hip-fracture rates are lower in developing than developed countries, which have diets that are higher in animal protein (2) . Crosssectional and longitudinal cohort studies have been inconsistent. Higher dietary protein has been associated with higher bone densities at some sites in younger premenopausal women and some but not all sites in postmenopausal women (3) (4) (5) (6) (7) (8) (9) (10) . The Framingham Osteoporosis Study suggested that elderly subjects with lower protein intake had greater bone loss at the femur and spine (11) . The Rancho Bernardo study showed a beneficial effect on the bone mineral density (BMD) 5 of women who consumed animal protein (12) . Cohort studies have also been inconsistent. In the Nurses' Health Study, there was a RR of 1.22 of forearm fracture in women who consumed .95 compared with ,68 g protein/d (13) . Conversely, in a Iowa study of postmenopausal women, risk of hip fracture decreased across increased quartiles of protein intake (14) . A protective effect against wrist fractures was seen with animal protein in meat eaters and vegetable protein in vegetarians in the Adventist 2 Health Study (15) . Sellmeyer et al (16) showed that the RR of hip fracture was 2.7 in women who consumed a higher ratio of animal to vegetable protein. This result was disproportionate to the modest effect on bone density. The effect of metabolic acidosis on muscle strength and risk of falls may have been responsible (16) .
The meta-analysis by Darling et al (17) of 61 cross-sectional and cohort studies and a recent review (18) suggested a very modest anabolic effect of dietary protein on bone health at the radius, hip, and lumbar spine (17, 18) . Important confounders included the interaction of dietary calcium with dietary protein and differing fruit and green vegetable intakes between studies (19, 20) . Fruit and vegetables provide dietary potassium, which can have an alkalinizing effect (21) . Also, increased salt intake antagonizes renal calcium reabsorption (22) .
The purpose of our study was to assess if a high-protein (HP) weight-loss diet was detrimental to bone health compared with a high-normal-protein (HNP) diet matched for energy. The study was performed in the context of weight loss because this is a very common clinical need, and HP weight-loss diets are frequently recommended.
SUBJECTS AND METHODS

Study design
This study was a randomized 2-y clinical trial conducted at the Commonwealth Scientific and Industrial Research Organization between February 2008 and May 2011. Subjects were enrolled in 2 cohorts in April 2008 and April 2009 to maximize recruitment. The trial was approved by the Commonwealth Scientific and Industrial Research Organization Ethics Committee, the procedures of which were followed throughout the study. The authors were responsible for the design, conduct, and analysis of the study and critically reviewed the manuscript. This trial was registered at the Australian and New Zealand Clinical Trials Registry (http://www.anzctr.org.au) as ACTRN12608000229370.
Study population and random assignment
The study population consisted of unpaid postmenopausal women aged 40-70 y with BMI (in kg/m 2 ) .27 who were recruited by using community newspaper advertisement. Postmenopausal status was confirmed by the absence of periods for 12 mo and a follicular stimulating hormone concentration .20 U/L. The weight of subjects could not have been .140 kg because of difficulties with scanning. Subjects provided informed written consent. Women with a total hip BMD t score less than 22.0 or a history of a low-trauma peripheral or spine fracture with a total hip BMD t score less than 21.0 were excluded.
Women were ineligible if they were taking hormone-replacement therapy, bisphosphonates, steroids, diuretics, calcium, or vitamin D. Subjects with parathyroid disease, a vitamin D concentration ,60 nmol/L with secondary hyperparathyroidism, or unstable metabolic, cardiac, gastrointestinal, renal, or other significant disease, including malignancies, were excluded.
Participants were block randomly assigned by trial coordinators to one of 2 diets by using the Clinstat program (Martin Bland; available from: http://www-users.york.ac.uk/~mb55/soft/soft.htm) matched for age, weight, smoking status, and use of selective serotonin reuptake inhibitor drugs. Although the investigators were blinded until the end of the study, subjects and dietitians were unblinded.
Diets
The HP diet plan contained #32% of calories as protein (.90 g/d) with low saturated and total fat (,10% and ,30%, respectively), whereas the normal protein (HNP) diet plan had #22% of calories as protein (,80 g/d), similar fat, and 55% of energy from low-glycemic index carbohydrates ( Table 1) . The diets were isocaloric and provided w5500 kJ/d. We aimed to achieve a difference in protein intake of $20 g/d between diets. The diets were constructed with the aim of providing w1300 mg Ca/d by using calcium-enriched foods but without any calcium supplements and sufficient fruit and vegetables to meet the Australian recommended daily intake for women aged 51-70 y. Patients received monthly group dietetic education and support Participants were instructed to record their dietary intakes by using a protein counter and checklist. Each diet group was allocated a protein target that was based on key protein foods as a compliance measure. Protein-compliance checklists were collected from each participant at each group session. Compliance to a diet was confirmed biochemically (see Study outcomes). Subjects also completed a food-frequency questionnaire (FFQ) at baseline and 1 and 2 y. This questionnaire has been previously validated (23) .
Study outcomes
The primary outcome was the change in BMD at 12 and 24 mo at the total hip, femoral neck, forearm ,and spine measured by using dual-energy X-ray absorptiometry (DXA) on a Norland XR-800 machine (Siemens Medical). The main secondary outcome was weight loss at 12 and 24 mo. At baseline and 3, 6, 12, and 24 mo, blood was sent to a certified commercial laboratory (Institute of Medical and Veterinary Science). Fasting C-terminal telopeptide, 25-hydroxyvitamin D, parathyroid hormone, osteocalcin, alkaline phosphatase, and biochemistry including calcium, phosphate, urea (expressed in this article after conversion to blood urea nitrogen), creatinine, and liver function were measured. At baseline and 3, 6, 12, 18, and 24 mo, 24-h urine for urea (shown in this article after conversion to urine urea nitrogen), creatinine, calcium, sodium, phosphate, and urine pH were measured. Compliance to the HP diet was assessed by reference to the blood urea nitrogen and 24-h urine for urea nitrogen excretion.
Statistical analysis
Results were analyzed with SPSS Statistics 19 (IBM) software. In Table 2 , means (6SEs) of variables of HP and HNP groups are shown and compared by using an independent t test for continuous variables and Fisher's exact test for categorical variables (2 tailed). We used a mixed-model ANCOVA by looking at the effect of diet (either the HP or HNP) and time-by-diet interaction (on the basis of measurements at baseline and 12 and 24 mo) on BMD at a given site as the dependent variable. We included covariates such as baseline weight, vitamin D, parathyroid hormone, serum C-terminal telopeptide, and baseline calcium intake at the site in question. A mixed-model ANCOVA was also used for the analysis of dietary and body-composition endpoints and measures of bone turnover and dietary compliance ( Tables 3-6 ). The results shown in Table 7 were analyzed as those shown in Table 2 . Significance was determined by using a P value , 0.05. Protein intake was estimated according to the following formulas: 
.
RESULTS
After the exclusion of ineligible volunteers, 323 subjects entered the trial with 164 subjects randomly assigned to receive the HP diet and 159 subjects randomly assigned to receive the HNP diet. A total of 186 subjects (90 subjects in the HP group and 96 subjects in the HNP group) completed 12 mo, and 137 subjects (69 subjects in the HP group and 68 subjects in the HNP group) completed 24 mo ( Figure 1 ).
Besides being matched as planned for BMI, age, smoking status, and selective serotonin reuptake inhibitor use, subjects in both groups had a similar baseline body composition, bone density, and markers of bone turnover and health such as vitamin D, parathyroid hormone, alkaline phosphatase, osteocalcin, and cross-laps as shown in Tables 2-5. The HNP cohort at baseline may have been consuming more dietary protein than the HP cohort did as shown by the 24-h urea excretion that was w7% higher than in the HP cohort (P , 0.02).
Changes in weight and body composition HP-diet subjects had a mean (6SE) loss of 8.6 6 0.7 kg at 12 mo and 7.9 6 0.9 kg at 24 mo, whereas HNP subjects lost 10.0 6 0.7 and 8.96 0.9 kg, respectively. At no time point was weight, fat mass, or lean mass significantly different between the 2 diet groups. Both diets achieved similar changes in total body fat and lean mass (Table 3) . At 24 mo, subjects lost 4.6% of lean mass with each diet and 12.9% fat mass in the HP group and 14.3% fat mass in the HNP group.
Bone density
As shown in Table 4 , there was a significant loss of bone over time at all sites (lumbar spine vertebrae 2-4 forearm, total hip, and femoral neck) as was expected in postmenopausal subjects.
Although there was a borderline significantly greater bone loss at 12 mo for the femoral neck (P = 0.05) only, this effect was not present at 24 mo. Overall, there was no effect of HP or HNP diet on bone density nor diet and time interaction at any of the 4 sites. The rate of bone loss, which was measured as the 1 All values are means 6 SEs. The analysis was conducted by using a mixed-model ANCOVA of the effect of diet and diet-time interaction on the bone density site of interest. In each case, we also included, as baseline covariates, 25-hydroxyvitamin D, parathyroid hormone, serum Ctelopeptide, baseline weight, and baseline calcium intake. Of the covariates tested in this model, 25-hydroxyvitamin D, parathyroid hormone, and baseline calcium intake had no effect on bone density at any site. Baseline weight (P , 0.001 for all sites) and serum C-telopeptide (P , 0.001 for forearm, P = 0.008 for femoral neck, P = 0.002 for total hip, P = 0.017 for lumbar spine) significantly affected bone density. There were no significant differences between HP and HNP groups for any measurement at baseline. HNP, high-normal protein; HP, high protein; L, lumbar spine vertebra.
2 There was no difference in the percentage bone loss at the spine, forearm, or total hip between HP and HNP groups at either 12 or 24 mo. There was a borderline significantly greater bone loss at 12 mo for the femoral neck (P = 0.05) but not at 24 mo.
percentage of bone loss from baseline, at each of the 4 sites was 1-2%/y as expected in a postmenopausal cohort (25) . At all sites at 2 y, there was a greater percentage of bone loss in the HNP group than HP group, though this result was not significant.
The significant relations between the change in bone density at each of the 4 sites and change in weight as well as fat mass (P # 0.005 for all analyses) are shown in Figure 2 . The relation was strongest at the hip (R 2 = 0.21) and weakest at the lumbar spine (R 2 = 0.05); these results suggested that weight loss accounted for only a small part of the change in BMD in these women.
Bone markers
Values of markers of bone metabolism and turnover are shown in Table 5 . Values are displayed for baseline and 12 and 24 mo, although P values were calculated by using all available measurements performed (see Study outcomes for time points). See Dietary compliance for a discussion of blood urea nitrogen and urine urea nitrogen results. Vitamin D was higher at baseline in the HNP than HP cohorts (but not significantly so). Vitamin D remained higher in the HNP group throughout the study with a significant result for time (P # 0.001) and diet (P = 0.012) but no interaction. Bone turnover was increased in the HNP group as shown by higher C-terminal telopeptide (P # 0.001 for time and diet by time, and P = 0.044 for diet) and osteocalcin (P # 0.001 for time and diet by time) compared with in the HP group. Urinary calcium increased over time in the HP group and decreased in the HNP group (diet-by-time interaction: P = 0.029). These changes mirrored the changes in calcium intake in the FFQ shown in Table 6 . The respective diets had no effect on urinary sodium, which was matched at all times. This result suggested that we were successful in eliminating the confounding effect of salt intake on bone loss. Urine pH was higher in the HNP group than HP group at baseline (but not significantly so) and remained higher during the study with a significant effect of diet (P = 0.009) but with no diet-by-time interaction (P = 0.42).
We performed post hoc analyses by using an independent t test to compare means between baseline and the corresponding means for that diet group for 12 and 24 mo and also for means 1 All values are means 6 SEs. The analysis was conducted by using a mixed-model ANCOVA of effect of diet and diet time interaction on a given variable. P values were calculated on all available measurements (eg, 0, 3, 6, 12, and 24 mo for blood tests and 0, 3, 6, 12, 18, and 24 mo for urine tests). There was no significant difference between measurements at baseline between HP and HNP groups except for urine urea nitrogen excretion, which was higher at baseline in the HNP group than in the HP group (P , 0.02). A post hoc analysis (independent t test) was conducted of the mean at baseline compared with the corresponding mean at 12 or 24 mo: # significant difference between 12 mo and baseline; *significant difference between 24 mo and baseline;^significant difference between 24 mo and 12 mo (all P , 0.001, except + P = 0.008). HNP, high-normal protein; HP, high protein.
2 n = 43 HP, n = 40 HNP.
between 12-24 mo for all variables where there was a diet-bytime interaction as shown in Tables 5 and 6 . For C-terminal telopeptide, changes were not significant between any time point for the HP group but were significant for the HNP group between baseline and 12 mo (P , 0.001) and 12 -24 mo (P = 0.008). A post hoc analysis for osteocalcin showed the drop in the HP group was significant between baseline and 24 mo and 12 and 24 mo (P , 0.001), whereas in the HNP group, there was a significant difference between baseline and 12 mo (P = 0.008) and 12 and 24 mo (P , 0.001).
Post hoc testing for 24-h urine calcium did not show a significant difference between baseline and either 12 or 24 mo for either HP or HNP diets.
Dietary compliance
There was a significant effect of diet and time by diet on blood urea nitrogen and 24-h urine urea nitrogen excretion that reflected the higher protein consumption in the HP group and lower consumption in the HNP group. Dietary protein intake calculated from urinary nitrogen (Table 5 ) and dietary data from the FFQ (Table 6) showed clear dietary separation between the 2 groups, albeit less than we had hoped. The urinary nitrogen suggested that protein intake increased from 78.4 to 89.1 g/d in the HP group at 1 y and 90.4 kg at 2 y. In the HNP group, protein intake dropped from 82.8 to 73.1 g/d at 1 y and 77.0 g at 2 y. These results equated to a 16-g difference at 1 y and 13.4-g difference at 2 y. We believe these findings were underestimates because the Maroni equation is not necessarily validated in situations of changing weight and body water and blood urea nitrogen. We believe that the FFQ was less accurate than our urinary nitrogen measurements. The FFQ underestimated the protein difference and overestimated baseline protein intake compared with results from the use of urine nitrogen. These results suggested that dietary separation was achieved by maintaining protein consumption in the HP group while reducing energy intake from other sources and reducing dietary protein in the HNP group, which was not completely consistent with the urinary nitrogen results. There was a significant diet-by-time effect that resulted in lower calcium intake in the HNP group, although the design of the diet ensured relative calcium sufficiency.
As presented in Table 5 , the post hoc analysis of blood urea nitrogen showed the significant diet-by-time interaction was a result of a significant rise of blood urea nitrogen in the HP group between baseline and 12 mo and baseline and 24 mo (P , 0.001 for both), whereas the reduction of blood urea nitrogen in the HNP group was not significant. The post hoc analysis showed a significant rise for urine urea nitrogen between baseline and 12 mo and baseline and 24 mo in the HP group (P , 0.001 for both). The fall in urine urea nitrogen in the HNP group was significant between baseline and 12 mo only (P , 0.001). 1 All values are means 6 SEs. The analysis was conducted by using a mixed-model ANCOVA in each case of the effect of diet and diettime interaction on the dietary macronutrient of interest. There was no significant difference between measurements at baseline between HP and HNP groups. A post hoc analysis was conducted by using the independent t test of the mean at baseline compared with the corresponding mean at 12 or 24 mo: # significant difference between 12 mo and baseline; *significant difference between 24 mo and baseline (both P , 0.001). HNP, high-normal protein; HP, high protein.
As presented in Table 6 , the post hoc analysis showed no significant change in protein intake in the HP group but a significant drop in protein intake in HNP group between baseline and 12 mo (P , 0.001) and baseline and 24 mo (P , 0.001). However, when we looked at protein as the percentage of energy, there was a significant difference between baseline and both 12 and 24 mo (P , 0.001) in the HP group and between baseline and 12 mo for the HNP diet.
For carbohydrate intake, the post hoc analysis showed that the diet-time interaction was achieved by reducing intake for the HP diet between baseline and 12 mo (P , 0.001) and baseline and 24 mo (P = 0.001), whereas no change was shown between time intervals in the HNP diet. For carbohydrate intake as a percentage of diet, we did not shown significant differences between time points with the HP diet, but there was a significant difference in carbohydrates as a percentage of energy with the HNP diet between baseline and 12 and 24 mo (P , 0.001) for both. For calcium intake, the post hoc analysis showed that the increase in intake for the HP diet was significant between baseline and 12 and 24 mo (P = 0.001 in each case), but no significance was shown with the HNP diet.
Fractures
Five subjects (3 subjects in the HP group and 2 subjects in the HNP group) experienced limb fractures during the study. None of the fractures were low-impact fractures.
Dropouts
As shown in Table 7 , baseline characteristics of subjects who dropped out before the end of the trial were matched between HP and HNP groups and were similar to the whole cohort, which suggested dropouts did not bias the results. The last recorded measurements of participants who did not complete the 24-mo trial are also shown in Table 7 . The 24-h urea nitrogen and serum blood urea nitrogen suggested dietary separation was achieved between subjects allocated to receive the HP or HNP diet. There was a more modest matched weight loss of 4.1 kg (HP) and 4.4 kg (HNP). The other bone markers were matched between dropouts assigned to receive HP and HNP diets.
DISCUSSION
There were 2 major aspects to our trial. First, we wanted sustained weight loss over a 2-y period of equal magnitude in both HP and HNP groups. Second, we aimed to tease out whether dietary protein is harmful or beneficial to bone health in situations of weight loss. It was important that weight and body-composition changes were similar in both groups to minimize the confounding effect of changed fat mass on bone density (26) .
Weight loss was successfully achieved in both groups with matched changes in lean and fat mass. Only a small number of weight-loss studies have been conducted for 2 y (27). In our study, 57.6% of participants completed 1 y and 42.4% of participants completed 2 y, which was consistent with the difficulties in maintaining lifestyle changes for this duration. The weight loss in completers (HP: 7.9 kg at 24 mo; HNP: 8.9 kg at 24 mo) compared favorably with results of studies such as by Sacks et al (27) , in which the average weight loss was 4.0 kg at 24 mo, although subject retention was higher. In the study of Sukumar et al (28) of the effects of weight loss on bone health in a similar cohort as ours, subjects lost 7.0 6 4.5% of body weight at 12 mo compared with 9.7 6 0.8% (HP) and 11.3 6 0.7% in the current study. The slight weight regains of 0.7 kg in the HP group and 1.1 kg in the HNP group reflected the difficulties in maintain a diet for 24 mo, particularly because the formal dietitian contact was reduced. Our urine urea nitrogen results confirmed that we successfully achieved dietary separation that equated to a 16-g difference in protein intake at 1 y and 13.4-g difference in protein intake at 2 y. These result were confirmed by FFQ analysis, although the absolute protein amounts consumed at baseline and throughout the study did not exactly correlate between the 2 methods. We had hoped to achieve a greater difference in protein intake between the 2 groups. Dansinger et al (29) , who compared the effect on weight loss at 1 y of 4 diets of different macronutrient compositions, have shown that it is possible to achieve successful weight loss despite poor adherence to the prescribed diet. Perhaps it is easier to achieve more ambitious macronutrient targets (eg, higher dietary protein) when weight loss is more modest than in trials when greater weight loss occurs. In the latter situation, the focus on caloric restriction may tend to reduce the consumption of all macronutrients. For example, Sukumar et al (28) achieved 26 g separation in protein intake between groups in the presence of more modest weight loss as previously discussed.
Some trials have relied predominantly on dietary records to corroborate achievement of protein targets and used significant differences in blood urea nitrogen or urinary nitrogen between groups as vindication rather than an attempt to calculate protein intake more directly from these measurements. Systemic underreporting of diets by obese subjects has been described (30, 31) . Dietary assessment is more reliable if independently verified by using an objective method such as 24-h urine nitrogen (32) .
The major barrier to determining the role of dietary protein in bone health is the absence of suitable intervention trials. Darling et al (17) could identify 12 protein supplementation trials with only 6 trials that were suitable for a meta-analysis, and then only at the lumbar spine. These trials were only of 3-6 mo duration. A modest effect on lumbar spine BMD for all protein (weighted mean difference: 0.02; 95% CI: 0.00, 0.04; P = 0.04) was seen. However, we are not aware of any other prospective randomized trial that compared HP and HNP diets for .1 y and assessed the effect on BMD.
This trial added to the body of evidence that refutes a harmful effect of dietary protein on bone health as originally postulated by Wachman and Bernstein (1), in this case, in the context of weight loss. Previous studies that have shown that protein was harmful have sometimes been in the context of inadequate dietary calcium or fruit and vegetables (33) . The hypercalciuria induced by dietary protein is balanced by increased calcium absorption in the presence of sufficient dietary calcium (34) . The fact that fruit and vegetables were replete in both diets supported the notion that any excess acidity from protein was neutralized. Although there was a difference between diets of urine pH, there was no time-by-diet effect.
A recent study (28) and the meta-analysis of Darling et al (17) have raised the possibility that dietary protein may actually improve bone health. Although we did not show an effect of diet or a diet-by-time interaction on bone-density sites, the percentage bone loss was lower on almost all measured occasions with the HP diet. Bone turnover was significantly higher in the HNP group than HP group. It is possible that if we had more subjects, the trial was longer, or we had achieved a greater difference in protein consumption between groups, there may have been a modest significant benefit for increased dietary protein consistent with the meta-analysis by Darling et al (17) . With the assumption of a power of 80% and significance of 0.05, we could have detected a difference in annual bone loss between groups that exceeded 1.3 percentage points at the spine and less at other sites. Extrapolation from the Framingham Osteoporosis Study suggested that a 20-g dietary protein increase over 2 y would slow down bone loss ,0.5%/y (11). The study by Sukumar et al (28) examined the effect of an HP and HNP calcium-sufficient weightloss diet on postmenopausal women of similar age and BMI to those in our study (28) . Although there were 47 subjects in the study of Sukumar et al (28) , the greater protein difference (26 g ) between groups resulted in a reduced loss of BMD in the HP group that varied between 0.8 and 2.4 percentage points at different sites.
At baseline, our women consumed 0.9 g protein $ kg 21 $ d 21 on the basis of urine nitrogen calculations. This amount is normal for Australian women but exceeds dietary recommendations of 0.8 g protein $ kg 21 $ d 21 (35) . There may be a threshold effect above which additional increases in dietary protein may be of limited benefit for bone health. The fact that baseline characteristics and last recorded measurements were similar between HP and HNP noncompleters was reassuring.
Why did we design a study that compared the effect of HP and HNP weight-loss diets on bone health as opposed to weightneutral diets? We felt that recruitment and adherence for 24 mo would be easier to achieve for subjects enrolled in a weight-loss diet. However, we had to separate the effect of the diet itself from the confounding effects of the loss of fat mass. A 10% weight loss in obese subjects results in a 1-2% drop in BMD (36) , but some authors have argued that this result is an artifact only (37, 38) . Although we showed a significant relation between the change in weight (and fat mass) and change in bone density, the relation was not as strong as shown by Skov et al (39) . Subjects in the study by Skov et al (39) were younger (mean age: 39 y), and their subjects, who were predominantly women, would have the protective effect of estrogen. However, Skov et al (39) used whole-body DXA scans whereby there may have been more opportunity for confounding by fat mass compared with in our study in which we studied bone sites of interest. We used a DXA scan because of its convenience and limited radiation for subjects. There is evidence that, with modalities such as quantitative computed tomography, which measures volumetric rather than areal bone density, we may have reduced measurement errors during weight loss. However, this effect may apply more to changes in a given individual rather than after changes at a group level (40) .
Exercise was not prescribed as part of the trial, and thus, we would not have expected it to be substantially different between FIGURE 2 . Relations between weight change and BMD change in the forearm (A), hip (B), femoral neck (C), and L2-L4 (D) and between fat-mass change and BMD change in the forearm (E), hip (F), femoral neck (G), and L2-L4 (H) at 24 mo (P # 0.005 for all analyses). Each dot represents the measurement for a given person, and the line is the trendline representing the best mathematical fit. BMD, bone mineral density; L, lumbar spine vertebra.
groups. However, any difference in exercise would have affected the nexus between protein intake and nitrogen excretion.
In conclusion, the hypothesis of Wachman and Bernstein (1) is not supported. This study, which was conducted in the context of weight loss, significantly adds to the existing body of evidence that an HP diet is not deleterious to bone health. Our results are more compatible with, but do not confirm, recent studies that suggest a marginally positive effect of dietary protein on bone. If present, this benefit is likely to be modest and difficult to translate into a significant clinical benefit.
